BusinessAdaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018By Nasdaq OMXApr 25, 2018, 12:02 PM UTC
BusinessAdaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual MeetingBy Nasdaq OMXApr 6, 2018, 12:00 PM UTC
BusinessAdaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business UpdateBy Nasdaq OMXMar 15, 2018, 11:30 AM UTC
BusinessAdaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cellsBy Nasdaq OMXMar 15, 2018, 11:30 AM UTC
BusinessAdaptimmune to Report Fourth Quarter / Full Year 2017 Financial Results and Business Update on Thursday March 15, 2018By Nasdaq OMXMar 5, 2018, 5:12 PM UTC
BusinessAdaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy CompanyBy Nasdaq OMXJan 8, 2018, 1:00 PM UTC
BusinessAdaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell DoseBy Nasdaq OMXJan 8, 2018, 1:00 PM UTC
